Analysis of platinum content in biodegradable carboplatin-impregnated beads and retrospective assessment of tolerability for intralesional use of the beads in dogs following excision of subcutaneous sarcomas: 29 cases (2011–2014)

Theresa A. Hess Oradell Animal Hospital, 580 Winters Ave, Paramus, NJ 07652.

Search for other papers by Theresa A. Hess in
Current site
Google Scholar
PubMed
Close
 DVM
,
Macy E. Drinkhouse Oradell Animal Hospital, 580 Winters Ave, Paramus, NJ 07652.

Search for other papers by Macy E. Drinkhouse in
Current site
Google Scholar
PubMed
Close
 VMD
,
Joshua D. Prey Roswell Park Cancer Institute, Elm and Carleton Streets, Buffalo, NY 14263.

Search for other papers by Joshua D. Prey in
Current site
Google Scholar
PubMed
Close
 MS
,
Jonathan M. Miller Oradell Animal Hospital, 580 Winters Ave, Paramus, NJ 07652.

Search for other papers by Jonathan M. Miller in
Current site
Google Scholar
PubMed
Close
 DVM
,
Arthur A. Fettig Oradell Animal Hospital, 580 Winters Ave, Paramus, NJ 07652.

Search for other papers by Arthur A. Fettig in
Current site
Google Scholar
PubMed
Close
 DVM
,
Carol A. Carberry Oradell Animal Hospital, 580 Winters Ave, Paramus, NJ 07652.

Search for other papers by Carol A. Carberry in
Current site
Google Scholar
PubMed
Close
 DVM
,
Stephen H. Brenn Oradell Animal Hospital, 580 Winters Ave, Paramus, NJ 07652.

Search for other papers by Stephen H. Brenn in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Dennis B. Bailey Oradell Animal Hospital, 580 Winters Ave, Paramus, NJ 07652.

Search for other papers by Dennis B. Bailey in
Current site
Google Scholar
PubMed
Close
 DVM

Abstract

OBJECTIVE To evaluate platinum content in biodegradable carboplatin-impregnated beads and retrospectively assess tolerability and outcome data for dogs treated by intralesional placement of such beads following surgical excision of subcutaneous sarcomas.

DESIGN Evaluation study and retrospective case series.

SAMPLE 9 carboplatin-impregnated beads and 29 client-owned dogs.

PROCEDURES Platinum content in 9 carboplatin-impregnated beads from 3 lots was measured by spectrophotometry, and calculated carboplatin content was compared with the labeled content. Medical records were searched to identify dogs with subcutaneous sarcomas for which treatment included placement of carboplatin-impregnated beads between 2011 and 2014. Signalment, tumor characteristics, surgical and histologic data, adverse events, and local recurrences were recorded. Associations between variables of interest and adverse events or local disease-free interval were analyzed.

RESULTS In vitro analysis identified a mean ± SD platinum content of 5.38 ± 0.97 mg/bead. Calculated carboplatin content (10.24 ± 1.84 mg/bead) was significantly greater than the labeled amount (4.6 mg/bead). Bead weight and total platinum content differed significantly among lots, but platinum content per bead weight did not. Mild-to-moderate local adverse events were reported for 11 of 29 tumors; all resolved without additional surgery. No dogs had signs of systemic toxicosis. Overall local disease-free rates 1, 2, and 3 years after surgery were 70%, 70%, and 58%, respectively, as determined by Kaplan-Meier analysis.

CONCLUSIONS AND CLINICAL RELEVANCE Carboplatin-impregnated beads were well tolerated; however, results of in vitro tests indicated that caution is needed because of manufacturing inconsistencies.

Abstract

OBJECTIVE To evaluate platinum content in biodegradable carboplatin-impregnated beads and retrospectively assess tolerability and outcome data for dogs treated by intralesional placement of such beads following surgical excision of subcutaneous sarcomas.

DESIGN Evaluation study and retrospective case series.

SAMPLE 9 carboplatin-impregnated beads and 29 client-owned dogs.

PROCEDURES Platinum content in 9 carboplatin-impregnated beads from 3 lots was measured by spectrophotometry, and calculated carboplatin content was compared with the labeled content. Medical records were searched to identify dogs with subcutaneous sarcomas for which treatment included placement of carboplatin-impregnated beads between 2011 and 2014. Signalment, tumor characteristics, surgical and histologic data, adverse events, and local recurrences were recorded. Associations between variables of interest and adverse events or local disease-free interval were analyzed.

RESULTS In vitro analysis identified a mean ± SD platinum content of 5.38 ± 0.97 mg/bead. Calculated carboplatin content (10.24 ± 1.84 mg/bead) was significantly greater than the labeled amount (4.6 mg/bead). Bead weight and total platinum content differed significantly among lots, but platinum content per bead weight did not. Mild-to-moderate local adverse events were reported for 11 of 29 tumors; all resolved without additional surgery. No dogs had signs of systemic toxicosis. Overall local disease-free rates 1, 2, and 3 years after surgery were 70%, 70%, and 58%, respectively, as determined by Kaplan-Meier analysis.

CONCLUSIONS AND CLINICAL RELEVANCE Carboplatin-impregnated beads were well tolerated; however, results of in vitro tests indicated that caution is needed because of manufacturing inconsistencies.

All Time Past Year Past 30 Days
Abstract Views 185 0 0
Full Text Views 1550 1241 102
PDF Downloads 404 94 8
Advertisement